AAPG
Ascentage Pharma Group Internat
Price Chart
Latest Quote
$17.20
-1.08 (-5.91%)
Current Price
| Previous Close | $18.28 |
| Open | $17.55 |
| Day High | $17.62 |
| Day Low | $17.10 |
| Volume | 13,258 |
Stock Information
Note: Financial values converted from CNY to USD
| Shares Outstanding | 93.34M |
| Total Debt | $292.64M |
| Cash Equivalents | $365.45M |
| Revenue | $84.87M |
| Net Income | $-183.71M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.61B |
| EPS (TTM) | $-2.06 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.29B |
| Sales | $84.87M |
| Income | $-183.71M |
| Book/sh | $2.11 |
| Cash/sh | $26.49 |
| Employees | 767 |
Financial Ratios
| Quick Ratio | 1.69 |
| Current Ratio | 1.79 |
| Debt/Eq | 148.38 |
Returns & Margins
| ROA | -23.02% |
| ROE | -154.56% |
| Gross Margin | 91.48% |
| Operating Margin | -193.35% |
| Profit Margin | -216.47% |
Ownership
| Institutional Ownership | 0.06% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -14.39 |
| P/S | 2.80 |
| P/B | 8.14 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $47.88 |
Technical Indicators
| SMA20 | $19.81 |
| SMA50 | $22.64 |
| SMA200 | $29.05 |
| RSI | 38.30 |
| ATR | 1.0666 |
| Shares Float | 222.84M |
| Short Ratio | 0.12 |
| Volatility | 0.65 |
| Rel Volume | 1.25 |
Performance History
| Week | -14.04% |
| Month | -20.26% |
| Quarter | -25.67% |
| 6 Months | -43.29% |
| YTD | -34.77% |
| Year | -39.20% |
| 10 Years | -1.04% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $17.20 | 13,258 |
| 2026-06-04 | $18.28 | 4,900 |
| 2026-06-03 | $17.87 | 22,700 |
| 2026-06-02 | $18.45 | 9,000 |
| 2026-06-01 | $19.08 | 8,300 |
| 2026-05-29 | $20.01 | 15,600 |
| 2026-05-28 | $19.88 | 24,100 |
| 2026-05-27 | $20.90 | 10,100 |
| 2026-05-26 | $20.13 | 6,300 |
| 2026-05-22 | $21.01 | 8,300 |
| 2026-05-21 | $20.66 | 4,800 |
| 2026-05-20 | $19.78 | 11,400 |
| 2026-05-19 | $18.99 | 6,600 |
| 2026-05-18 | $18.56 | 9,300 |
| 2026-05-15 | $19.50 | 29,200 |
| 2026-05-14 | $20.18 | 9,200 |
| 2026-05-13 | $21.38 | 3,600 |
| 2026-05-12 | $21.16 | 12,100 |
| 2026-05-11 | $21.66 | 1,500 |
| 2026-05-08 | $21.50 | 2,300 |
| 2026-05-07 | $21.70 | 2,900 |
| 2026-05-06 | $21.57 | 5,200 |
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
đ° Latest News
Ascentage Pharma (AAPG) Reports Phase 1b Olverembatinib Data
Insider Monkey âĸ 2026-06-05T21:03:38Z
Global Growth Companies Insiders Favor With Up To 40% Earnings Growth
Simply Wall St. âĸ 2026-05-25T09:35:57Z
Global Growth Companies With High Insider Ownership In April 2026
Simply Wall St. âĸ 2026-04-22T09:35:49Z
Global Growth Companies With High Insider Ownership
Simply Wall St. âĸ 2026-04-20T09:35:53Z
Global Insights Into 3 Growth Stocks With High Insider Ownership
Simply Wall St. âĸ 2026-04-17T09:36:19Z
Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer Says
MT Newswires âĸ 2026-03-27T15:26:50ZA Look At Ascentage Pharma Group Internationalâs Valuation After Recent Share Price Moves
Simply Wall St. âĸ 2026-03-09T05:05:52Z
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target
Insider Monkey âĸ 2026-02-11T20:16:28Z
Ascentage Pharma Receives Clearance from Chinaâs CDE for New Drug
Exec Edge âĸ 2026-02-06T23:13:57Z
Is Ascentage Pharma Group (SEHK:6855) Price Swings Creating A Valuation Opportunity Now
Simply Wall St. âĸ 2026-01-15T17:08:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $7,215,866 | $4,288,558 | $4,503,539 | $3,243,586 |
| Cost Of Revenue | $7,215,866 | $4,288,558 | $4,503,539 | $3,243,586 |
| Total Revenue | $84,653,500 | $144,595,999 | $32,731,350 | $30,921,707 |
| Operating Revenue | $73,617,227 | $138,491,605 | $28,536,569 | $30,921,707 |
| Expenses | ||||
| Interest Expense | $7,972,575 | $9,503,834 | $14,163,522 | $7,783,103 |
| Total Expenses | $261,252,008 | $199,112,370 | $161,400,778 | $156,225,460 |
| Other Income Expense | $-9,792,245 | $160,720 | $504,571 | $839,870 |
| Other Non Operating Income Expenses | $-8,170,452 | $-654,822 | $-206,724 | $-451,194 |
| Net Non Operating Interest Income Expense | $4,136,686 | $-3,924,359 | $-9,384,843 | $-6,348,865 |
| Interest Expense Non Operating | $7,972,575 | $9,503,834 | $14,163,522 | $7,783,103 |
| Operating Expense | $254,036,142 | $194,823,811 | $156,897,239 | $152,981,874 |
| Other Operating Expenses | $-2,137,423 | $-1,337,806 | $-2,854,320 | $-4,953,849 |
| Selling And Marketing Expense | $52,143,914 | $28,899,737 | $28,809,645 | $23,211,591 |
| General And Administrative Expense | $36,313,922 | $27,591,420 | $26,699,500 | $25,154,086 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-183,245,220 | $-59,780,747 | $-136,484,380 | $-130,186,384 |
| Net Interest Income | $4,136,686 | $-3,924,359 | $-9,384,843 | $-6,348,865 |
| Interest Income | $12,109,261 | $5,579,475 | $4,778,679 | $1,434,238 |
| Normalized Income | $-181,994,151 | $-60,423,478 | $-137,032,783 | $-131,511,780 |
| Net Income From Continuing And Discontinued Operation | $-183,245,220 | $-59,780,747 | $-136,484,380 | $-130,186,384 |
| Net Income Common Stockholders | $-183,245,220 | $-59,780,747 | $-136,484,380 | $-130,186,384 |
| Net Income | $-183,245,220 | $-59,780,747 | $-136,484,380 | $-130,186,384 |
| Net Income Including Noncontrolling Interests | $-183,277,364 | $-59,817,167 | $-136,495,438 | $-130,186,384 |
| Net Income Continuous Operations | $-183,277,364 | $-59,817,167 | $-136,495,438 | $-130,186,384 |
| Pretax Income | $-182,254,067 | $-58,280,010 | $-137,549,700 | $-130,812,748 |
| Special Income Charges | $-2,654 | $-7,372 | $590 | $304,925 |
| Earnings From Equity Interest | $46,299 | $-41,433 | $158,655 | $-40,991 |
| Interest Income Non Operating | $12,109,261 | $5,579,475 | $4,778,679 | $1,434,238 |
| Operating Income | $-176,598,508 | $-54,516,371 | $-128,669,428 | $-125,303,754 |
| Gross Profit | $77,437,634 | $140,307,441 | $28,227,811 | $27,678,120 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-0.79 | $-1.93 | $-1.98 |
| Basic EPS | - | $-0.79 | $-1.93 | $-1.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $-417,023 | $214,244 | $4,236 | $6,660 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-159,861,998 | $-35,895,461 | $-110,197,294 | $-115,084,938 |
| Total Unusual Items | $-1,668,092 | $856,974 | $552,639 | $1,332,056 |
| Total Unusual Items Excluding Goodwill | $-1,668,092 | $856,974 | $552,639 | $1,332,056 |
| Reconciled Depreciation | $12,751,402 | $13,737,689 | $13,741,523 | $9,276,763 |
| EBITDA (Bullshit earnings) | $-161,530,091 | $-35,038,487 | $-109,644,655 | $-113,752,883 |
| EBIT | $-174,281,492 | $-48,776,176 | $-123,386,178 | $-123,029,646 |
| Diluted NI Availto Com Stockholders | $-183,245,220 | $-59,780,747 | $-136,484,380 | $-130,186,384 |
| Minority Interests | $32,144 | $36,420 | $11,059 | $0 |
| Tax Provision | $1,023,297 | $1,537,157 | $-1,054,261 | $-626,364 |
| Gain On Sale Of Ppe | $-2,654 | $-7,372 | $590 | $304,925 |
| Gain On Sale Of Security | $-1,665,438 | $864,347 | $552,050 | $1,027,131 |
| Research And Development | $167,715,729 | $139,670,461 | $104,242,413 | $109,570,046 |
| Selling General And Administration | $88,457,836 | $56,491,157 | $55,509,146 | $48,365,677 |
| Other Gand A | $36,313,922 | $27,591,420 | $26,699,500 | $25,154,086 |
| Diluted Average Shares | - | $11,134,699 | $10,406,196 | $9,720,173 |
| Basic Average Shares | - | $11,134,699 | $10,406,196 | $9,720,173 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Other Special Charges | - | - | $-590 | $-304,925 |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-05-27
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $181,927,467 | $24,108,229 | $-7,331,614 | $44,184,609 |
| Total Assets | $584,426,020 | $385,993,833 | $368,680,798 | $417,319,550 |
| Total Non Current Assets | $150,310,243 | $168,629,914 | $170,482,907 | $176,020,802 |
| Non Current Prepaid Assets | $101,740 | $359,628 | $442,347 | $958,419 |
| Non Current Deferred Assets | $9,113,536 | $11,024,035 | $8,823,651 | $8,005,604 |
| Non Current Deferred Taxes Assets | $4,712,032 | $6,522,560 | $8,823,651 | $8,005,604 |
| Investmentin Financial Assets | $589,797 | $168,239 | $287,673 | $384,695 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $589,797 | $168,239 | $287,673 | $384,695 |
| Goodwill And Other Intangible Assets | $13,363,316 | $14,846,949 | $16,240,048 | $16,071,661 |
| Other Intangible Assets | $9,722,206 | $11,205,840 | $12,598,939 | $12,430,552 |
| Current Assets | $434,115,777 | $217,363,919 | $198,197,890 | $241,298,748 |
| Restricted Cash | $838,248 | $3,632,115 | $3,617,960 | $2,447,803 |
| Prepaid Assets | $21,281,187 | $15,818,344 | $10,415,512 | $10,809,644 |
| Inventory | $4,219,699 | $972,722 | $2,383,810 | $1,393,099 |
| Receivables | $44,402,981 | $14,608,376 | $24,113,832 | $9,066,500 |
| Other Receivables | $214,538 | $904,895 | $978,620 | $95,694 |
| Taxes Receivable | $6,892,952 | $1,444,117 | $1,623,415 | $956,060 |
| Accounts Receivable | $37,295,491 | $12,259,364 | $21,511,797 | $8,014,745 |
| Cash Cash Equivalents And Short Term Investments | $363,373,661 | $182,332,363 | $157,666,776 | $217,581,702 |
| Cash And Cash Equivalents | $363,373,661 | $182,332,363 | $157,666,776 | $217,581,702 |
| Cash Equivalents | $187,056,338 | $50,645,536 | $4,607,491 | $19,168,388 |
| Cash Financial | $176,317,322 | $131,686,827 | $153,059,285 | $198,413,313 |
| Non Current Accounts Receivable | - | $3,838,691 | $1,039,811 | - |
| Other Non Current Assets | - | - | - | $1,150,546 |
| Debt | ||||
| Total Debt | $291,907,864 | $246,018,448 | $264,758,939 | $264,336,054 |
| Long Term Debt And Capital Lease Obligation | $111,654,092 | $131,146,426 | $173,870,699 | $187,900,927 |
| Long Term Debt | $109,455,183 | $128,080,516 | $171,965,066 | $186,552,652 |
| Current Debt And Capital Lease Obligation | $180,253,772 | $114,872,022 | $90,888,240 | $76,435,128 |
| Current Debt | $179,179,900 | $113,480,249 | $89,449,578 | $75,244,033 |
| Other Current Borrowings | $179,179,900 | $113,480,249 | $89,449,578 | $75,244,033 |
| Net Debt | - | $59,228,403 | $103,747,869 | $44,214,984 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $387,697,608 | $345,568,882 | $358,266,170 | $357,063,280 |
| Total Non Current Liabilities Net Minority Interest | $145,383,820 | $173,553,093 | $220,523,164 | $227,138,175 |
| Other Non Current Liabilities | $1,773,961 | $925,096 | - | - |
| Non Current Deferred Liabilities | $31,955,767 | $41,481,572 | $43,954,294 | $34,027,723 |
| Non Current Deferred Taxes Liabilities | $0 | $791,507 | $1,555,441 | $1,791,655 |
| Current Liabilities | $242,313,788 | $172,015,789 | $137,743,005 | $129,925,105 |
| Other Current Liabilities | $290,180 | - | - | $416,101 |
| Current Deferred Liabilities | $8,859,482 | $7,974,787 | $5,663,521 | $3,590,976 |
| Payables And Accrued Expenses | $52,910,354 | $49,168,980 | $41,191,244 | $49,482,899 |
| Payables | $34,589,209 | $37,099,383 | $34,101,595 | $44,191,687 |
| Other Payable | $16,830,435 | $22,119,583 | $22,182,691 | $29,043,057 |
| Total Tax Payable | $2,020,053 | $1,419,493 | $1,236,951 | $1,058,537 |
| Accounts Payable | $15,738,721 | $13,560,308 | $10,681,953 | $14,090,092 |
| Tradeand Other Payables Non Current | - | $0 | $2,698,172 | $5,209,526 |
| Interest Payable | - | - | $154,232 | $56,473 |
| Equity | ||||
| Common Stock Equity | $195,290,783 | $38,955,178 | $8,908,435 | $60,256,271 |
| Total Equity Gross Minority Interest | $196,728,412 | $40,424,951 | $10,414,628 | $60,256,271 |
| Stockholders Equity | $195,290,783 | $38,955,178 | $8,908,435 | $60,256,271 |
| Gains Losses Not Affecting Retained Earnings | $-84,984,081 | $-75,285,467 | $-74,382,341 | $-76,454,443 |
| Other Equity Adjustments | $-58,578,005 | $-56,696,406 | $-54,768,656 | $-52,968,892 |
| Retained Earnings | $-1,034,108,592 | $-850,863,372 | $-791,082,625 | $-654,598,245 |
| Long Term Equity Investment | $4,870,245 | $4,824,094 | $2,506,340 | $2,347,685 |
| Other | ||||
| Ordinary Shares Number | $55,045,962 | $46,479,654 | $42,789,233 | $39,101,440 |
| Share Issued | $55,045,962 | $46,479,654 | $42,789,233 | $39,101,440 |
| Tangible Book Value | $181,927,467 | $24,108,229 | $-7,331,614 | $44,184,609 |
| Invested Capital | $483,925,866 | $280,515,943 | $270,323,079 | $322,052,956 |
| Working Capital | $191,801,989 | $45,348,130 | $60,454,885 | $111,373,644 |
| Capital Lease Obligations | $3,272,781 | $4,457,682 | $3,344,294 | $2,539,369 |
| Total Capitalization | $304,745,966 | $167,035,694 | $180,873,501 | $246,808,923 |
| Minority Interest | $1,437,629 | $1,469,773 | $1,506,193 | $0 |
| Foreign Currency Translation Adjustments | $-26,406,077 | $-18,589,061 | $-19,613,685 | $-23,485,552 |
| Treasury Stock | $436,597 | $1,180 | $3,148,187 | $3,915,070 |
| Additional Paid In Capital | $1,314,782,306 | $965,073,642 | $877,492,539 | $795,197,488 |
| Capital Stock | $37,747 | $31,554 | $29,047 | $26,541 |
| Common Stock | $37,747 | $31,554 | $29,047 | $26,541 |
| Non Current Deferred Revenue | $31,955,767 | $40,690,065 | $42,398,853 | $32,236,068 |
| Long Term Capital Lease Obligation | $2,198,909 | $3,065,910 | $1,905,633 | $1,348,275 |
| Current Deferred Revenue | $8,859,482 | $7,974,787 | $5,663,521 | $3,590,976 |
| Current Capital Lease Obligation | $1,073,872 | $1,391,772 | $1,438,661 | $1,191,094 |
| Current Accrued Expenses | $18,321,145 | $12,069,597 | $7,089,650 | $5,291,212 |
| Investments And Advances | $5,460,042 | $4,992,333 | $2,794,014 | $2,732,380 |
| Investmentsin Joint Venturesat Cost | $4,870,245 | $4,824,094 | $2,506,340 | $2,347,685 |
| Goodwill | $3,641,109 | $3,641,109 | $3,641,109 | $3,641,109 |
| Net PPE | $122,271,610 | $133,568,278 | $141,143,035 | $95,845,627 |
| Accumulated Depreciation | $-42,322,179 | $-32,651,580 | $-22,239,901 | $-10,406,223 |
| Gross PPE | $164,593,789 | $166,219,858 | $163,382,936 | $106,251,850 |
| Leases | $8,955,176 | $6,523,003 | $4,308,169 | $1,141,404 |
| Construction In Progress | $338,248 | $1,119,729 | $1,889,561 | $6,015,040 |
| Machinery Furniture Equipment | $27,511,355 | $27,033,768 | $26,520,940 | $22,885,876 |
| Buildings And Improvements | $124,052,943 | $127,640,675 | $126,594,966 | $71,973,611 |
| Land And Improvements | $3,736,066 | $3,902,684 | $4,069,301 | $4,235,919 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-616,337 | $0 | - | - |
| Finished Goods | $1,095,105 | $569,301 | $1,633,442 | $650,251 |
| Work In Process | $3,740,932 | $403,421 | $750,369 | $742,849 |
| Investment Properties | - | - | $0 | $52,407,111 |
| Other Properties | - | - | - | $95,653,501 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-05-27
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-177,189,484 | $-20,000,886 | $-115,441,028 | $-131,359,195 |
| Operating Activities | ||||
| Operating Cash Flow | $-173,124,164 | $-16,419,494 | $-107,059,429 | $-96,419,204 |
| Cash Flow From Continuing Operating Activities | $-173,124,164 | $-16,419,494 | $-107,059,429 | $-96,419,204 |
| Operating Gains Losses | $1,454,586 | $-938,219 | $-814,362 | $-2,730,906 |
| Investing Activities | ||||
| Capital Expenditure | $-4,065,320 | $-3,581,392 | $-8,381,599 | $-34,939,991 |
| Investing Cash Flow | $-147,456,807 | $-53,381,749 | $3,232,380 | $-56,710,709 |
| Cash Flow From Continuing Investing Activities | $-147,456,807 | $-53,381,749 | $3,232,380 | $-56,710,709 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,332,350 | $0 | $-873,341 | $-3,948,098 |
| Issuance Of Capital Stock | $339,856,260 | $78,728,994 | $69,313,039 | $0 |
| Financing Cash Flow | $374,535,561 | $46,412,123 | $54,372,018 | $91,310,534 |
| Cash Flow From Continuing Financing Activities | $374,535,561 | $46,412,123 | $54,372,018 | $91,310,534 |
| Net Other Financing Charges | $-1,729,284 | $-1,958,567 | $1,517,252 | - |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $338,523,910 | $78,728,994 | $68,439,698 | $-3,948,098 |
| Common Stock Issuance | $339,856,260 | $78,728,994 | $69,313,039 | $0 |
| Other | ||||
| Repayment Of Debt | $-137,674,294 | $-100,451,643 | $-142,562,233 | $-9,988,647 |
| Issuance Of Debt | $182,979,959 | $79,021,385 | $140,592,755 | $112,594,670 |
| End Cash Position | $176,317,322 | $131,686,827 | $153,059,285 | $198,413,313 |
| Beginning Cash Position | $131,686,827 | $153,059,285 | $198,413,313 | $251,678,873 |
| Effect Of Exchange Rate Changes | $-9,324,094 | $2,016,662 | $4,101,003 | $8,553,820 |
| Changes In Cash | $53,954,589 | $-23,389,120 | $-49,455,031 | $-61,819,379 |
| Interest Paid Cff | $-7,565,320 | $-8,928,930 | $-13,616,633 | $-7,350,192 |
| Proceeds From Stock Option Exercised | $590 | $885 | $1,180 | $2,802 |
| Common Stock Payments | $-1,332,350 | $0 | $-873,341 | $-3,948,098 |
| Net Issuance Payments Of Debt | $45,305,665 | $-21,430,258 | $-1,969,478 | $102,606,023 |
| Net Long Term Debt Issuance | $45,305,665 | $-21,430,258 | $-1,969,478 | $102,606,023 |
| Long Term Debt Payments | $-137,674,294 | $-100,451,643 | $-142,562,233 | $-9,988,647 |
| Long Term Debt Issuance | $182,979,959 | $79,021,385 | $140,592,755 | $112,594,670 |
| Net Investment Purchase And Sale | $-137,000,746 | $-46,038,045 | $14,560,897 | $-19,168,388 |
| Purchase Of Investment | $-137,000,746 | $-46,038,045 | $0 | $-19,168,388 |
| Net Business Purchase And Sale | $-6,390,741 | $-3,762,312 | $-2,948,983 | $-2,948,983 |
| Purchase Of Business | $-6,390,741 | $-3,762,312 | $-2,948,983 | $-2,948,983 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-1,583,014 | $-4,965,350 |
| Purchase Of Intangibles | $0 | $0 | $-1,583,014 | $-4,965,350 |
| Net PPE Purchase And Sale | $-4,065,320 | $-3,581,392 | $-6,796,521 | $-29,627,988 |
| Sale Of PPE | $0 | $0 | $2,064 | $346,653 |
| Purchase Of PPE | $-4,065,320 | $-3,581,392 | $-6,798,585 | $-29,974,641 |
| Taxes Refund Paid | $-4,276 | $0 | $0 | $0 |
| Change In Working Capital | $-21,159,394 | $16,361,841 | $-1,348,570 | $15,395,607 |
| Change In Other Working Capital | $-2,585,816 | $588,322 | $11,065,173 | $-637,570 |
| Change In Other Current Assets | $4,096,727 | $-7,217,635 | $-523,739 | $4,332,056 |
| Change In Payables And Accrued Expense | $18,959,453 | $14,453,997 | $3,753,908 | $12,112,357 |
| Change In Payable | $18,959,453 | $14,453,997 | $3,753,908 | $12,112,357 |
| Change In Account Payable | $2,178,414 | $2,878,355 | $-3,408,139 | $3,641,699 |
| Change In Prepaid Assets | $-12,730,316 | $-2,126,364 | $-1,156,149 | $459,599 |
| Change In Inventory | $-3,863,315 | $1,411,088 | $-990,711 | $-813,624 |
| Change In Receivables | $-25,036,127 | $9,252,434 | $-13,497,052 | $-57,210 |
| Changes In Account Receivables | $-25,036,127 | $9,252,434 | $-13,497,052 | $-57,210 |
| Other Non Cash Items | $12,226,188 | $9,491,301 | $14,163,522 | $7,752,876 |
| Stock Based Compensation | $3,077,853 | $3,085,226 | $4,645,090 | $3,259,363 |
| Unrealized Gain Loss On Investment Securities | $167,207 | $122,678 | $103,067 | $1,439,841 |
| Asset Impairment Charge | $616,337 | $0 | $0 | - |
| Depreciation Amortization Depletion | $12,751,402 | $13,737,689 | $13,741,523 | $9,276,763 |
| Depreciation And Amortization | $12,751,402 | $13,737,689 | $13,741,523 | $9,276,763 |
| Amortization Cash Flow | $1,483,633 | $1,599,971 | $1,533,324 | $1,442,347 |
| Amortization Of Intangibles | $1,483,633 | $1,599,971 | $1,533,324 | $1,442,347 |
| Depreciation | $11,267,768 | $12,137,718 | $12,208,199 | $7,834,415 |
| Earnings Losses From Equity Investments | $-46,299 | $41,433 | $-158,655 | $40,991 |
| Net Foreign Currency Exchange Gain Loss | $1,498,231 | $-987,025 | $-239,015 | $398,555 |
| Gain Loss On Sale Of PPE | $2,654 | $7,372 | $-590 | $-304,925 |
| Net Income From Continuing Operations | $-182,254,067 | $-58,280,010 | $-137,549,700 | $-130,812,748 |
| Sale Of Investment | - | - | $14,560,897 | $0 |
| Gain Loss On Investment Securities | - | - | $-416,101 | $-2,865,527 |
| Change In Other Current Liabilities | - | - | - | $0 |
Fetched: 2026-05-27